Effects of S-11701 on accumulation, release and metabolism of norepinephrine in isolated canine saphenous veins.
1. The effects S-11701 ([morpholinyl-2)-methoxy]-8-tetrahydro-1,2,3,4 quinoline) on accumulation, overflow and metabolism of [3H]norepinephrine were investigated in isolated canine saphenous veins. 2. Saphenous veins were incubated with [3H]norepinephrine in the absence or the presence of S-11701; the drug caused a concentration-dependent inhibition of the tissue content of [3H]norepinephrine and its metabolites, except for 3-methoxy-4-hydroxymandelic acid (VMA). 3. In helical strips of canine saphenous veins previously incubated with [3H]norepinephrine and then suspended for isometric tension recording and measurement of the overflow of labelled transmitter and its metabolites, S-11701 (30 microM) significantly increased the spontaneous efflux of total 3H; this effect was almost exclusively due to an augmentation of the efflux of [3H]DOPEG. 4. During electrical stimulation (9 V, 1 Hz), S-11701 at 1 microM slightly increased the overflow of extraneuronal norepinephrine metabolites without affecting the contractile response. At the higher concentration (30 microM) the compound increased the contractive response and the overflow of 3H; the latter was due mainly to an increase in [3H]DOPEG and, to a lesser extent, in [3H]norepinephrine. 5. DMI (1 microM) did not interfere with the effects of S-11701 on DOPEG efflux. 6. These experiments indicate that in the canine saphenous vein, S-11701 causes a concentration-dependent inhibition of neuronal accumulation of [3H]norepinephrine. At higher concentrations, S-11701 enters the adrenergic nerve terminals independently of the neuronal amine carrier and displaces [3H]norepinephrine from its storage sites.
Guo
H Y
HY
Department of Medicine, Baylor College of Medicine, Houston, TX 77030.
Lorenz
R R
RR
Verbeuren
T J
TJ
Vanhoutte
P M
PM
D000818:Animals; D003891:Desipramine / Q000494:pharmacology; D004285:Dogs; D004558:Electric Stimulation; D066298:In Vitro Techniques; D007537:Isometric Contraction / Q000187:drug effects; D008734:Methoxyhydroxyphenylglycol / Q000031:analogs & derivatives / Q000378:metabolism; D009025:Morpholines / Q000494:pharmacology*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism*; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D014179:Neurotransmitter Uptake Inhibitors / Q000494:pharmacology*; D009638:Norepinephrine / Q000378:metabolism*; D011804:Quinolines / Q000494:pharmacology*; D012501:Saphenous Vein / Q000187:drug effects / Q000378:metabolism; D014642:Vanilmandelic Acid / Q000378:metabolism
D009025:Morpholines; D014179:Neurotransmitter Uptake Inhibitors; D011804:Quinolines; C079319:(morpholinyl-2-methoxy)-8-tetrahydro-1,2,3,4-quinoline; D008734:Methoxyhydroxyphenylglycol; D014642:Vanilmandelic Acid; D003891:Desipramine; C010117:3,4-dihydroxyphenylglycol; D009638:Norepinephrine